View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2016	Aug. 05, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Entity Registrant Name	ASSEMBLY BIOSCIENCES, INC.
Entity Central Index Key	0001426800
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	ASMB
Entity Common Stock, Shares Outstanding		17,225,554

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 20,341,338	$ 27,107,526
Marketable securities, at fair value	43,205,005	40,556,652
Other current assets	556,644	704,287
Total current assets	64,102,987	68,368,465
Long-term assets
Marketable securities, at fair value	11,167,421	23,392,129
Property, plant and equipment, net	113,679	148,609
Security deposits	183,698	197,158
Intangible assets	29,000,000	29,000,000
Goodwill	12,638,136	12,638,136
Total long-term assets	53,102,934	65,376,032
Total assets	117,205,921	133,744,497
Current liabilities
Accounts payable	2,413,922	1,363,698
Accrued expenses	2,630,946	2,039,204
Total current liabilities	5,044,868	3,402,902
Long-term liabilities
Deferred tax liabilities	11,600,000	11,600,000
Total long-term liabilities	11,600,000	11,600,000
Total liabilities	16,644,868	15,002,902
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding	0	0
Common stock, $0.001 par value; 50,000,000 shares authorized; 17,225,554 and 17,225,662 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively	17,226	17,226
Additional paid-in capital	286,489,852	283,511,859
Accumulated other comprehensive loss	(839,362)	(821,585)
Accumulated deficit	(185,106,663)	(163,965,905)
Total stockholders' equity	100,561,053	118,741,595
Total liabilities and stockholders' equity	$ 117,205,921	$ 133,744,497

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	17,225,554	17,225,662
Common stock, shares outstanding	17,225,554	17,225,662

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Operating expenses:
Research and development	$ 7,519,031	$ 4,667,754	$ 15,637,607	$ 8,502,188
General and administrative	2,935,099	2,486,151	6,093,675	5,854,935
Total operating expenses	10,454,130	7,153,905	21,731,282	14,357,123
Loss from operations	(10,454,130)	(7,153,905)	(21,731,282)	(14,357,123)
Other income (expenses)
Interest and other income	444,605	211,234	935,026	269,499
Realized loss from marketable securities	(142,675)	0	(344,502)	0
Total other income	301,930	211,234	590,524	269,499
Net loss	(10,152,200)	(6,942,671)	(21,140,758)	(14,087,624)
Unrealized loss recognized in accumulated other comprehensive loss before reclassification	(232,542)	(134,219)	(362,279)	(134,219)
Reclassification adjustment of unrealized loss included in net loss	142,675	0	344,502	0
Comprehensive loss	$ (10,242,067)	$ (7,076,890)	$ (21,158,535)	$ (14,221,843)
Net loss per share, basic and diluted	$ (0.59)	$ (0.41)	$ (1.23)	$ (0.99)
Weighted average common shares outstanding, basic and diluted	17,225,660	17,119,488	17,225,661	14,164,451

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (21,140,758)	$ (14,087,624)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	37,093	30,397
Stock-based compensation	2,977,993	5,206,024
Realized loss from marketable securities	344,502	0
Changes in operating assets and liabilities:
Other current assets	147,643	(479,878)
Accounts payable	1,050,224	396,694
Accrued expenses	591,742	888,459
Security deposits	13,460	(10,079)
Net cash used in operating activities	(15,978,100)	(8,056,007)
Cash flows from investing activities
Purchases of fixed assets	(2,163)	(47,991)
Purchases of marketable securities	(7,951,257)	(48,780,784)
Redemptions of marketable securities	17,165,332	0
Net cash provided by (used in) investing activities	9,211,912	(48,828,775)
Cash flows from financing activities
Proceeds from common stock sold, net of underwriters' discounts and cost	0	81,014,989
Proceeds from exercise of stock options	0	296,825
Net cash provided by financing activities	0	81,311,814
Net (decrease) increase in cash and cash equivalents	(6,766,188)	24,427,032
Cash and cash equivalents at the beginning of the period	27,107,526	29,091,113
Cash and cash equivalents at the end of the period	20,341,338	53,518,145
Supplemental disclosure of cash flow information:
Change in unrealized loss on marketable securities available-for-sale	(17,777)	(134,219)
Cashless exercise of warrants	$ 0	$ 88

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 118,741,595	$ 17,226	$ 283,511,859	$ (821,585)	$ (163,965,905)
Balance (in shares) at Dec. 31, 2015		17,225,662
Stock-based compensation	2,977,993	$ 0	2,977,993	0	0
Change in unrealized loss on marketable securities	(17,777)	0	0	(17,777)	0
Cancellation of common stock	0	$ 0	0	0	0
Cancellation of common stock (in shares)		(108)
Net loss	(21,140,758)	$ 0	0	0	(21,140,758)
Balance at Jun. 30, 2016	$ 100,561,053	$ 17,226	$ 286,489,852	$ (839,362)	$ (185,106,663)
Balance (in shares) at Jun. 30, 2016		17,225,554

Business

6 Months Ended

Jun. 30, 2016

Organization, Business and Basis Of Presentation [Abstract]

Business

Note 1 - Business

Overview

Assembly Biosciences, Inc. (“Assembly” or the “Company”) is a biotechnology company advancing two innovative platform programs: (i) HBV-cure program, which is advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and (ii) microbiome program, which is a novel class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome.

The Company’s HBV-cure program is aimed at increasing the current low cure rates for patients with HBV and is pursuing several drug candidates that inhibit multiple viral targets throughout the HBV lifecycle for possible use alone or in combination therapy. Assembly has discovered several novel core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of HBV core protein (HBc) functions.

The Company’s microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices (cGMP) conditions, and a patent-pending delivery system, GEMICEL^TM, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead program from this platform, ABI-M101, is in development for the treatment of C. difficile- infections (CDI). Using its microbiome platform, the Company is developing additional product candidates for multiple indications including metabolic disorders, immunotherapy and autoimmune diseases.

Liquidity

The Company has not derived any revenue from product sales to date as it currently has no approved products. Once a product has been developed, it will need to be approved for sale by the U.S. Food and Drug Administration (FDA) or an applicable foreign regulatory agency. Since inception, the Company’s operations have been financed primarily through the sale of equity securities, the proceeds from the exercise of warrants and stock options and issuance of debt. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues its product development efforts. Management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months. If the Company cannot generate significant cash from its operations, it intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, grants or other arrangements. The Company cannot assure such funding will be available on reasonable terms, if at all.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Summary Of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated.

The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (SEC) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2016, condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2016 and 2015, condensed consolidated statements of cash flows for the six months ended June 30, 2016 and 2015, and condensed consolidated statement of changes in stockholders’ equity for the six months ended June 30, 2016 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2016 are not necessarily indicative of results to be expected for the year ending December 31, 2016 or for any future interim period. The consolidated balance sheet at December 31, 2015 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2015, and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC on March 11, 2016 (the “2015 Annual Report”).

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates inherent in the preparation of the accompanying financial statements include recoverability and useful lives (indefinite) of intangible assets, assessment of impairment of goodwill, and the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.

The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2015 Annual Report.

Reclassification

Certain reclassifications have been made to previous period amounts to conform to the current period presentation on the condensed consolidated statements of operations and comprehensive loss. The unrealized loss on available-for-sale securities has been included in accumulated other comprehensive income, and the amount of losses reclassified out of accumulated other comprehensive income into realized loss from marketable securities when the securities were sold during the three and six months ended June 30, 2016.

Loss per Share of Common Stock

Basic net loss per share of common stock excludes dilution and is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Since the Company has only incurred losses, basic and diluted net loss per share is the same. Securities that could potentially result in diluted loss per share in the future that were not included in the computation of diluted loss per share at June 30, 2016 and 2015 are as follows:

	Six Months Ended June 30,
	2016		2015
Warrants to purchase common stock		16,909		56,776
Options to purchase common stock		4,097,952		3,176,519
Total		4,114,861		3,233,295

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also results in enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively and improves guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. ASU 2014-09 will have no impact on the Company until it begins to generate revenue.

In June 2014, the FASB issued ASU 2014-12, Compensation-Stock Compensation (Topic 718). ASU 2014-12 clarifies how entities should treat performance targets that can be achieved after the requisite service period of a share-based payment award. The accounting standard is effective for interim and annual periods beginning after December 15, 2015. ASU 2014-12 will have no impact on the Company until it begins to grant performance awards.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known, and reasonably knowable, at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its condensed consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015-17 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. Adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 will be effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-01 will have on its condensed consolidated financial statements and related disclosures.

In February 2016, FASB issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard will be effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the impact that ASU 2016-02 will have on its condensed consolidated financial statements and related disclosures.

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in ASU 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU 2016-09 on its condensed consolidated financial statements and related disclosures.

In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customer. The new guidance is an update to ASC 606 and provides clarity on: identifying performance obligations and licensing implementation. For public companies, ASU 2016-10 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016. The Company is currently evaluating the impact that ASU No. 2016-10 will have on its condensed consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The new standard will be effective on January 1, 2020. Early adoption will be available on January 1, 2019. The Company is currently evaluating the effect that the updated standard will have on its condensed consolidated financial statements and related disclosures.

Marketable Securities

6 Months Ended

Jun. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

Note 3 - Marketable Securities

Marketable securities consist of the following as of June 30, 2016 and December 31, 2015:

	June 30, 2016
	Amortized Cost		Gross Unrealized Gain			Gross Unrealized Loss	Fair Value
Short-term available-for-sale securities
Corporate bonds	$	41,201,117	$	523	$	(833,051)	$	40,368,589
Government and agency obligations		1,225,000		3,944		-		1,228,944
Municipal bonds		1,596,160		11,312		-		1,607,472
		44,022,277		15,779		(833,051)		43,205,005

Long-term available-for-sale securities
Corporate bonds		11,189,511		31,729		(53,819)		11,167,421
		11,189,511		31,729		(53,819)		11,167,421
Total	$	55,211,788	$	47,508	$	(886,870)	$	54,372,426

	December 31, 2015
	Amortized Cost		Gross Unrealized Loss		Fair Value
Short-term available-for-sale securities
Corporate bonds	$	41,126,524	$	(569,872)	$	40,556,652
		41,126,524		(569,872)		40,556,652

Long-term available-for-sale securities
Government and agency obligations		1,225,000		(3,834)		1,221,166
Municipal bonds		1,596,160		(4,384)		1,591,776
Corporate bonds		20,822,682		(243,495)		20,579,187
		23,643,842		(251,713)		23,392,129
Total	$	64,770,366	$	(821,585)	$	63,948,781

The contractual term to maturity of short-term marketable securities held by the Company as of June 30, 2016 is less than one year. The contractual term to maturity of long-term marketable securities held by the Company as of June 30, 2016 is 1 to 2 years.

The fair value of marketable securities was classified into fair value measurement categories as of June 30, 2016 as follows:

Quoted prices in active markets for identical assets (Level 1)	$	-
Quoted prices for similar assets observable in the marketplace (Level 2)		54,372,426
Significant unobservable inputs (Level 3)		-
Total	$	54,372,426

The fair values of marketable securities are determined using quoted market prices from daily exchange traded markets based on the closing prices as of June 30, 2016 and December 31, 2015.

There were no transfers of marketable securities between Levels 1, 2 and 3 for the six months ended June 30, 2016.

The following table shows the Company’s investments’ gross unrealized losses and fair value, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position, at June 30, 2016.

	Less than 12 Months				12 Months or More				Total
	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate bonds	$	9,282,011	$	(53,993)	$	34,182,760	$	(832,877)	$	43,464,771	$	(886,870)
Total	$	9,282,011	$	(53,993)	$	34,182,760	$	(832,877)	$	43,464,771	$	(886,870)

The Company has determined that the unrealized losses are deemed to be temporary impairments as of June 30, 2016. The Company believes that the unrealized losses generally are caused by increases in the risk premiums required by market participants rather than an adverse change in cash flows or a fundamental weakness in the credit quality of the issuer or underlying assets. Because the Company has the ability and intent to hold these investments until a recovery of fair value, which may be maturity, it does not consider the investment in corporate bonds to be other-than-temporarily impaired at June 30, 2016.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Property, Plant and Equipment, Net

6 Months Ended

Jun. 30, 2016

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

Note 4 - Property, Plant and Equipment, Net

Property, plant and equipment, consists of the following:

		June 30,		December 31,
	Useful life (Years)	2016		2015
Computer hardware and software	3	$	86,228	$	84,065
Lab equipment	3 to 5		177,782		177,782
Office equipment	3 to 5		1,109		1,109
Total property, plant and equipment			265,119		262,956
Less: Accumulated depreciation and amortization			(151,440)		(114,347)
Property, plant and equipment, net		$	113,679	$	148,609

Depreciation expense for the three months ended June 30, 2016 and 2015 was approximately $18,000 and $16,000, respectively, and was recorded in both research and development expense and general and administrative expense in the condensed consolidated statements of operations.

Depreciation expense for the six months ended June 30, 2016 and 2015 was approximately $37,000 and $30,000, respectively, and was recorded in both research and development expense and general and administrative expense in the condensed consolidated statements of operations.

Accrued Expenses

6 Months Ended

Jun. 30, 2016

Payables and Accruals [Abstract]

Accrued Expenses

Note 5 - Accrued Expenses

Accrued expenses consist of the following:

	June 30,		December 31,
	2016		2015
Accrued expenses:
Salaries, bonuses and employee benefits	$	1,619,978	$	1,628,975
Severance accrued for former CEO		-		106,777
Research and development expenses		624,554		120,700
General and administrative expenses		386,414		-
Other		-		182,752
Total accrued expenses	$	2,630,946	$	2,039,204

Stockholders' Equity

6 Months Ended

Jun. 30, 2016

Stockholders' Transactions [Abstract]

Stockholders' Equity

Note 6 - Stockholders’ Equity

Common Stock

On July 10, 2014, the Company’s stockholders approved a 1-for-5 reverse stock split of the issued and outstanding shares of the Company’s common stock, par value $0.001 per share, effective as of July 11, 2014 at 5:01 p.m. Eastern time (the “Split Effective Time”). At the Split Effective Time, all shares of common stock issued and outstanding immediately prior to the Split Effective Time, including shares issued to the shareholders of Assembly Pharmaceuticals, Inc. in connection with the acquisition of Assembly Pharmaceuticals, Inc., were automatically reclassified into a smaller number of shares such that each five shares of issued common stock immediately prior to the Split Effective Time were reclassified into one share of common stock. Proportional adjustments to outstanding warrants, options and other equity awards and equity compensation were also made. No fractional shares were issued and, in lieu thereof, any person who would otherwise be entitled to a fractional share of common stock as a result of the reverse stock split was entitled to receive a cash payment equal to the fraction to which such holder would otherwise be entitled multiplied by the closing price per share of common stock on the NASDAQ Capital Market on July 11, 2014, which was $1.45. On June 29, 2016, the Company cancelled 108 shares of common stock, which represented the aggregate number of fractional shares that were cashed out as a result of the reverse stock split.

Options

In July 2010, the stockholders approved the 2010 Equity Incentive Plan (the “2010 Plan”), under which, as of June 30, 2016, there were outstanding options to purchase an aggregate of 728,793 shares of common stock. Effective on June 2, 2016, the 2010 Plan was frozen and no further grants will be made under the 2010 Plan. Shares that are forfeited under the 2010 Plan on or after June 2, 2016 will become available for issuance under the Amended and Restated 2014 Plan (as defined below).

In July 2014, the stockholders approved the 2014 Stock Incentive Plan (the “2014 Plan”). On June 2, 2016, at the 2016 Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders of the Company approved the amendment and restatement of the Company’s 2014 Plan (the “Amended and Restated 2014 Plan”). Pursuant to the terms of the Amended and Restated 2014 Plan, the maximum number of shares reserved for issuance thereunder is 4,160,000 (representing an increase of 1,600,000). As of June 30, 2016, there were outstanding options to purchase an aggregate of 2,747,508 shares of common stock and 1,340,403 shares available for grant under the Amended and Restated 2014 Plan. Additionally, 6,667 shares of common stock forfeited under the 2010 Plan since June 2, 2016 are available for issuance under the Amended and Restated 2014 Plan.

A summary of the Company’s option activity and related information for the six-month period ended June 30, 2016 is as follows:

	Number of Shares		Weighted Average Exercise Price		Total Intrinsic Value
Outstanding as of December 31, 2015		3,367,784	$	7.16	$	3,971,205
Granted		757,500		6.64		-
Forfeited		(27,332)		8.32		-
Outstanding as of June 30, 2016		4,097,952	$	7.05	$	2,070,098
Options vested and exercisable		2,265,890	$	6.58	$	1,624,454

The fair value of the options granted for the six months ended June 30, 2016 and 2015, were based on the following assumptions:

	Six Months Ended June 30,
	2016		2015
Exercise price		$5.84 - $7.03		$9.42 - $16.55
Expected stock price volatility		88.2% - 91.8%		90.7% - 95.6%
Risk-free rate of interest		1.36% - 1.94%		1.49% - 2.08%
Term (years)		5.4 - 7.0		5.1 - 6.6

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

	Future Stock Option Compensation Expenses
Six months ended December 31, 2016	$	1,959,807
Year ended December 31, 2017		1,959,182
Year ended December 31, 2018		828,835
Year ended December 31, 2019		271,022
Year ended December 31, 2020		14,095
Total	$	5,032,941

Unamortized stock-based compensation expense amounted to $5.0 million at June 30, 2016, and will be amortized over 3.9 years.

Stock-based compensation expense for the three and six months ended June 30, 2016 and 2015 is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Research and development	$	850,851	$	1,419,872	$	1,569,007	$	2,475,302
General and administrative		667,287		1,200,372		1,408,986		2,730,722
Total stock-based compensation expense	$	1,518,138	$	2,620,244	$	2,977,993	$	5,206,024

Warrants

There was no warrant activity for the six months ended June 30, 2016. The weighted average remaining contractual life of 16,909 shares of outstanding warrants at June 30, 2016 is approximately 3.9 years.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Commitments

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments

Note 7 - Commitments

Real Property Leases

The Company leases office space for corporate and administrative functions in New York, NY under an agreement with a monthly lease payment of $10,130 that expires in August 2016, which will be extended on a month to month basis. The Company also leases office space in Carmel, IN under a lease agreement that expires in June 2021. The leased locations in New York, NY and Carmel, IN are for corporate and administrative functions supporting both the HBV-cure and microbiome programs and are adequate for the Company’s current needs.

The Company leases office and laboratory space in San Francisco, California under a sublease that expires in December 2017. Research activities for the HBV-cure program are also being conducted at laboratory space leased from Indiana University at Bloomington, IN that expires in December 2016. Research activities for the microbiome program will also be conducted at office and laboratory space leased from the University of Florida Research Foundation in Alachua, FL. The Company believes these leased facilities are adequate for its current needs and that additional space will be available in the future on commercially reasonable terms as needed.

The total leasing expenses for the three months ended June 30, 2016 and 2015 were approximately $402,637 and $138,000, respectively. The total leasing expenses for the six months ended June 30, 2016 and 2015 were approximately $755,000 and $297,000, respectively.

Equipment Lease

Pursuant to a Master Lease agreement dated November 25, 2014, the Company leases certain equipment. The equipment lease expense for the three months ended June 30, 2016 and 2015 amounted to approximately $165,000 and $28,000, respectively. The equipment lease expense for the six months ended June 30, 2016 and 2015 amounted to approximately $256,000 and $47,000, respectively.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2016

Summary Of Significant Accounting Policies [Abstract]

Basis of presentation

Basis of Presentation

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated.

Use of Estimates

Use of Estimates

Significant Accounting Policies

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2015 Annual Report.

Reclassification

Reclassification

Loss per Share of Common Stock

Loss per Share of Common Stock

	Six Months Ended June 30,
	2016		2015
Warrants to purchase common stock		16,909		56,776
Options to purchase common stock		4,097,952		3,176,519
Total		4,114,861		3,233,295

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Summary Of Significant Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Securities that could potentially result in diluted loss per share in the future that were not included in the computation of diluted loss per share at June 30, 2016 and 2015 are as follows:

	Six Months Ended June 30,
	2016		2015
Warrants to purchase common stock		16,909		56,776
Options to purchase common stock		4,097,952		3,176,519
Total		4,114,861		3,233,295

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation

Marketable securities consist of the following as of June 30, 2016 and December 31, 2015:

	June 30, 2016
	Amortized Cost		Gross Unrealized Gain			Gross Unrealized Loss	Fair Value
Short-term available-for-sale securities
Corporate bonds	$	41,201,117	$	523	$	(833,051)	$	40,368,589
Government and agency obligations		1,225,000		3,944		-		1,228,944
Municipal bonds		1,596,160		11,312		-		1,607,472
		44,022,277		15,779		(833,051)		43,205,005

Long-term available-for-sale securities
Corporate bonds		11,189,511		31,729		(53,819)		11,167,421
		11,189,511		31,729		(53,819)		11,167,421
Total	$	55,211,788	$	47,508	$	(886,870)	$	54,372,426

	December 31, 2015
	Amortized Cost		Gross Unrealized Loss		Fair Value
Short-term available-for-sale securities
Corporate bonds	$	41,126,524	$	(569,872)	$	40,556,652
		41,126,524		(569,872)		40,556,652

Long-term available-for-sale securities
Government and agency obligations		1,225,000		(3,834)		1,221,166
Municipal bonds		1,596,160		(4,384)		1,591,776
Corporate bonds		20,822,682		(243,495)		20,579,187
		23,643,842		(251,713)		23,392,129
Total	$	64,770,366	$	(821,585)	$	63,948,781

Schedule Of Available For Sale Securities Fair Value Measurement Categories

The fair value of marketable securities was classified into fair value measurement categories as of June 30, 2016 as follows:

Quoted prices in active markets for identical assets (Level 1)	$	-
Quoted prices for similar assets observable in the marketplace (Level 2)		54,372,426
Significant unobservable inputs (Level 3)		-
Total	$	54,372,426

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value

	Less than 12 Months				12 Months or More				Total
	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate bonds	$	9,282,011	$	(53,993)	$	34,182,760	$	(832,877)	$	43,464,771	$	(886,870)
Total	$	9,282,011	$	(53,993)	$	34,182,760	$	(832,877)	$	43,464,771	$	(886,870)

Property, Plant and Equipment, Net (Tables)

6 Months Ended

Jun. 30, 2016

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment, consists of the following:

		June 30,		December 31,
	Useful life (Years)	2016		2015
Computer hardware and software	3	$	86,228	$	84,065
Lab equipment	3 to 5		177,782		177,782
Office equipment	3 to 5		1,109		1,109
Total property, plant and equipment			265,119		262,956
Less: Accumulated depreciation and amortization			(151,440)		(114,347)
Property, plant and equipment, net		$	113,679	$	148,609

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2016

Payables and Accruals [Abstract]

Schedule Accrued Expenses

Accrued expenses consist of the following:

	June 30,		December 31,
	2016		2015
Accrued expenses:
Salaries, bonuses and employee benefits	$	1,619,978	$	1,628,975
Severance accrued for former CEO		-		106,777
Research and development expenses		624,554		120,700
General and administrative expenses		386,414		-
Other		-		182,752
Total accrued expenses	$	2,630,946	$	2,039,204

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company’s option activity and related information for the six-month period ended June 30, 2016 is as follows:

	Number of Shares		Weighted Average Exercise Price		Total Intrinsic Value
Outstanding as of December 31, 2015		3,367,784	$	7.16	$	3,971,205
Granted		757,500		6.64		-
Forfeited		(27,332)		8.32		-
Outstanding as of June 30, 2016		4,097,952	$	7.05	$	2,070,098
Options vested and exercisable		2,265,890	$	6.58	$	1,624,454

Assumptions for Weighted Average Fair Value of Options Granted

The fair value of the options granted for the six months ended June 30, 2016 and 2015, were based on the following assumptions:

	Six Months Ended June 30,
	2016		2015
Exercise price		$5.84 - $7.03		$9.42 - $16.55
Expected stock price volatility		88.2% - 91.8%		90.7% - 95.6%
Risk-free rate of interest		1.36% - 1.94%		1.49% - 2.08%
Term (years)		5.4 - 7.0		5.1 - 6.6

Estimated Future Stock Based Expenses Relating to Unvested Stock Options

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

	Future Stock Option Compensation Expenses
Six months ended December 31, 2016	$	1,959,807
Year ended December 31, 2017		1,959,182
Year ended December 31, 2018		828,835
Year ended December 31, 2019		271,022
Year ended December 31, 2020		14,095
Total	$	5,032,941

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Stock-based compensation expense for the three and six months ended June 30, 2016 and 2015 is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Research and development	$	850,851	$	1,419,872	$	1,569,007	$	2,475,302
General and administrative		667,287		1,200,372		1,408,986		2,730,722
Total stock-based compensation expense	$	1,518,138	$	2,620,244	$	2,977,993	$	5,206,024

Summary of Significant Accounting Policies (Details) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,114,861	3,233,295
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	16,909	56,776
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,097,952	3,176,519

Marketable Securities (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 55,211,788	$ 64,770,366
Gross Unrealized Gain	47,508
Gross Unrealized Loss	(886,870)	(821,585)
Fair Value	54,372,426	63,948,781
Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	44,022,277	41,126,524
Gross Unrealized Gain	15,779
Gross Unrealized Loss	(833,051)	(569,872)
Fair Value	43,205,005	40,556,652
Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	11,189,511	23,643,842
Gross Unrealized Gain	31,729
Gross Unrealized Loss	(53,819)	(251,713)
Fair Value	11,167,421	23,392,129
US Government Agencies Debt Securities [Member] \| Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,225,000
Gross Unrealized Gain	3,944
Gross Unrealized Loss	0
Fair Value	1,228,944
US Government Agencies Debt Securities [Member] \| Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,225,000
Gross Unrealized Loss		(3,834)
Fair Value		1,221,166
Corporate Bond Securities [Member] \| Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	41,201,117	41,126,524
Gross Unrealized Gain	523
Gross Unrealized Loss	(833,051)	(569,872)
Fair Value	40,368,589	40,556,652
Corporate Bond Securities [Member] \| Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	11,189,511	20,822,682
Gross Unrealized Gain	31,729
Gross Unrealized Loss	(53,819)	(243,495)
Fair Value	11,167,421	20,579,187
Municipal Bonds [Member] \| Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,596,160
Gross Unrealized Gain	11,312
Gross Unrealized Loss	0
Fair Value	$ 1,607,472
Municipal Bonds [Member] \| Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,596,160
Gross Unrealized Loss		(4,384)
Fair Value		$ 1,591,776

Marketable Securities (Details 1) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	$ 54,372,426	$ 63,948,781
Fair Value, Inputs, Level 1 [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	0
Fair Value, Inputs, Level 2 [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	54,372,426
Fair Value, Inputs, Level 3 [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	$ 0

Marketable Securities (Details 2)	Jun. 30, 2016 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Fair Value, Less than 12 Months	$ 9,282,011
Unrealized Losses, Less than 12 Months	(53,993)
Fair Value, 12 Months or More	34,182,760
Unrealized Losses,12 Months or More	(832,877)
Fair Value, Total	43,464,771
Unrealized Losses, Total	(886,870)
Corporate Bond Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Fair Value, Less than 12 Months	9,282,011
Unrealized Losses, Less than 12 Months	(53,993)
Fair Value, 12 Months or More	34,182,760
Unrealized Losses,12 Months or More	(832,877)
Fair Value, Total	43,464,771
Unrealized Losses, Total	$ (886,870)

Marketable Securities - Additional Information (Details)	6 Months Ended
	Jun. 30, 2016
Short-term Investments [Member]
Available For Sale Securities Maturity Term	less than one year
Other Long-term Investments [Member]
Available For Sale Securities Maturity Term	1 to 2 years

Property, Plant and Equipment, Net (Details) - USD ($)	6 Months Ended
Property, Plant and Equipment, Net (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 265,119	$ 262,956
Less: Accumulated depreciation and amortization	(151,440)	(114,347)
Property, plant and equipment, net	113,679	148,609
Computer hardware and software [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 86,228	84,065
Property, Plant and Equipment, Useful Life	3 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 177,782	177,782
Lab equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Lab equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 1,109	$ 1,109
Office equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Office equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 18,000	$ 16,000	$ 37,093	$ 30,397

Accrued Expenses (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Accrued expenses:
Salaries, bonuses and employee benefits	$ 1,619,978	$ 1,628,975
Severance accrued for former CEO	0	106,777
Research and development expenses	624,554	120,700
General and administrative expenses	386,414	0
Other	0	182,752
Total accrued expenses	$ 2,630,946	$ 2,039,204

Stockholders' Equity (Details) - Stock Option [Member]	6 Months Ended
Stockholders' Equity (Details) - Stock Option [Member]	Jun. 30, 2016 USD ($) $ / shares shares
Number of Shares
Option, Outstanding at beginning of period \| shares	3,367,784
Option, Granted \| shares	757,500
Option, Forfeited \| shares	(27,332)
Option, Outstanding at end of period \| shares	4,097,952
Options vested and exercisable \| shares	2,265,890
Weighted Average Exercise Price
Option, Outstanding at beginning of period \| $ / shares	$ 7.16
Option, Granted \| $ / shares	6.64
Option, Forfeited \| $ / shares	8.32
Option, Outstanding at end of period \| $ / shares	7.05
Options vested and exercisable \| $ / shares	$ 6.58
Total Intrinsic Value
Option, Outstanding at beginning of period \| $	$ 3,971,205
Option, Granted \| $	0
Option, Forfeited \| $	0
Option, Outstanding at end of period \| $	2,070,098
Options vested and exercisable \| $	$ 1,624,454

Stockholders' Equity (Details 1) - $ / shares	6 Months Ended
Stockholders' Equity (Details 1) - $ / shares	Jun. 30, 2016	Jun. 30, 2015
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Exercise price	$ 7.03	$ 16.55
Expected stock price volatility	91.80%	95.60%
Risk-free rate of interest	1.94%	2.08%
Term (years)	7 years	6 years 7 months 6 days
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Exercise price	$ 5.84	$ 9.42
Expected stock price volatility	88.20%	90.70%
Risk-free rate of interest	1.36%	1.49%
Term (years)	5 years 4 months 24 days	5 years 1 month 6 days

Stockholders' Equity (Details 2)	Jun. 30, 2016 USD ($)
Stockholders Equity Note [Line Items]
Six months ended December 31, 2016	$ 1,959,807
Year ended December 31, 2017	1,959,182
Year ended December 31, 2018	828,835
Year ended December 31, 2019	271,022
Year ended December 31, 2020	14,095
Total	$ 5,032,941

Stockholders' Equity (Details 3) - USD ($)	3 Months Ended		6 Months Ended
Stockholders' Equity (Details 3) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 1,518,138	$ 2,620,244	$ 2,977,993	$ 5,206,024
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	850,851	1,419,872	1,569,007	2,475,302
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 667,287	$ 1,200,372	$ 1,408,986	$ 2,730,722

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Stockholders Equity Note [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 5.0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 10 months 24 days
Common Stock Par Or Stated Value Per Share	$ 0.001	$ 0.001
Class of Warrant or Right, Outstanding	16,909
Warrant [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 10 months 24 days
Amended and Restated 2014 Plan [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	6,667
Common Stock [Member]
Stockholders Equity Note [Line Items]
Stockholders' Equity, Reverse Stock Split	1-for-5 reverse stock split
Stock Repurchased and Retired During Period, Shares	108
Common Stock Par Or Stated Value Per Share	$ 0.001
2010 Stock Incentive Plan [Member]
Stockholders Equity Note [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number	728,793
2014 Stock Incentive Plan [Member]
Stockholders Equity Note [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number	2,747,508
Common Stock, Capital Shares Reserved for Future Issuance	4,160,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	1,340,403
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	1,600,000

Commitments - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense	$ 402,637	$ 138,000	$ 755,000	$ 297,000
Operating Lease Expiration Month and Year			2016-08
Operating Leases, Rent Expense, Net, Total			$ 10,130
Equipment Lease [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense	$ 165,000	$ 28,000	$ 256,000	$ 47,000
San Francisco [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Lease Expiration Month and Year			2017-12